A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways

Martin F. M. de Rooij; Yvonne J. Thus; Nathalie Swier; Roderick L. Beijersbergen; Steven T. Pals; Marcel Spaargaren

doi:10.1038/s41467-022-29835-y

Nature Communications (Apr 2022)

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways

Martin F. M. de Rooij,
Yvonne J. Thus,
Nathalie Swier,
Roderick L. Beijersbergen,
Steven T. Pals,
Marcel Spaargaren

Affiliations

Martin F. M. de Rooij: Department of Pathology, Amsterdam UMC location University of Amsterdam
Yvonne J. Thus: Department of Pathology, Amsterdam UMC location University of Amsterdam
Nathalie Swier: Department of Pathology, Amsterdam UMC location University of Amsterdam
Roderick L. Beijersbergen: Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute
Steven T. Pals: Department of Pathology, Amsterdam UMC location University of Amsterdam
Marcel Spaargaren: Department of Pathology, Amsterdam UMC location University of Amsterdam

DOI: https://doi.org/10.1038/s41467-022-29835-y
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 11

Abstract

Read online

Targeting integrin-mediated retention of malignant B cells in their protective microenvironment is an efficacious treatment for lymphoma and leukemia. Here, the authors present an unbiased loss-of-adhesion CRISPR screening method, identifying therapeutic targets for these B-cell malignancies.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal